Oncology News

Health care professionals who experienced recent weight loss had a significantly higher risk for a cancer diagnosis during the subsequent 12 months, results of a prospective cohort analysis revealed.

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.

The FDA has granted breakthrough device designation to Amadix’s PreveCol, a blood test for early detection of colorectal cancer, intended to screen adults aged 45 years or older without apparent symptoms, according to a company release.

Glecirasib exhibited antitumor activity among patients with pancreatic ductal adenocarcinoma and other solid tumors harboring the KRAS G12C mutation variant, study findings presented at ASCO Gastrointestinal Cancers Symposium showed.

Patients diagnosed with cryptogenic pyogenic liver abscess had a “significantly higher incidence” of colorectal cancer up to 3 years from diagnosis compared with matched controls, highlighting the importance of CRC screening, data showed.

Cancer mortality in the U.S. is projected to decline again in 2024, but the number of new diagnoses should top 2 million for the first time, an annual report from the American Cancer Society revealed.

Glucagon-like peptide 1 receptor agonists significantly lowered the risk for colorectal cancer in patients with type 2 diabetes compared with other diabetes medications, according to a research letter in JAMA Oncology.

Facility fees for three common colonoscopy procedures were approximately 55% higher at hospitals compared with ambulatory surgery centers in the same county and with the same insurer, researchers reported in JAMA Health Forum.

Results of a phase 1 trial for a vaccine targeting micrometastatic disease markers in patients already treated for pancreatic or colorectal cancer showed potential in preventing recurrence, according to a study in Nature Medicine.

Colorectal cancer incidence has increased since 1988 among men but not women younger than 50 years, suggesting that patient sex should be factored in when determining screening age, data from an Austrian study showed.